Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Vaxxinity Inc
VAXXVaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida. Address: 505 Odyssey Way, Merritt Island, FL, United States, 32953
Analytics
Precio Objetivo de WallStreet
15 USDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave VAXX
Análisis de dividendos VAXX
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout VAXX
Valoración de la acción VAXX
Finanzas VAXX
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |